-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $15 Price Target

Benzinga·02/18/2026 11:55:01
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $15 price target.